Drug
Afm24
Afm24: highest development phase Phase 1/2, developed by Affimed. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Affimed
Trials
| Drug | Phase | Indication |
|---|---|---|
| 14 mg AFM24 NCT04259450 | Phase 1/2 | Advanced Solid Tumor |
| AFM24 NCT05109442 | Phase 1/2 | Advanced Solid Tumor |
| AFM24 NCT05099549 | Phase 1/2 | Squamous Cell Carcinoma of Head and Neck |
Latest
No recent events.
Follow Afm24 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.